Skip to main content
All lobbying filings

THE NICKLES GROUP, LLC

Lobbying for UCB, INC. · Biopharmaceutical company

 Filing 4th Quarter - Report
4th Quarter (Oct 1 - Dec 31) 2025 · Georgia · House · Senate · $60,000.00 income · posted Jan 20, 2026

Official filing document

 Bills named in this filing 5
  • HR 993
    Emerging Innovative Border Technologies Act
  • HR 1
    An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
  • HR 591
    Defending American Jobs and Investment Act
  • HR 2423
    Unfair Tax Prevention Act
  • S 864
    HELP Copays Act
 Lobbying activity 4
Medicare/Medicaid

Monitored the implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to drug pricing. Issues related to access to home infusion, including H.R. 993, Joe Fiandra Access to Home infusion Act of 2025. Issues related to pharmacy benefit management reforms. Issues related to Most Favored Nation drug pricing.

Taxation/Internal Revenue Code

Monitor implementation of H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to corporate and international taxes. Monitor OECD negotiations related to Pillar II global minimum tax. H.R. 591, Defending American Jobs and Investment Act, and H.R. 2423, Unfair Tax Prevention Act, as they relate to multinational corporations.

Health Issues

Issues related to medication step therapy. S.864, HELP Copays Act, as it relates to out-of-pocket costs for prescription drugs. Issues related to pharmacy benefit management reforms.

Trade (domestic/foreign)

Issues related to tariffs.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem